Summary
Guardant Health, Inc. (GH) announced the closing of a successful secondary offering of its common stock on May 25, 2023, raising approximately $380.5 million in net proceeds. The offering included the sale of 14,375,000 shares at a public price of $28.00 per share, with the underwriters exercising their option to purchase additional shares in full. This capital infusion provides the company with significant financial flexibility to support its ongoing operations, research and development, and growth initiatives in the precision oncology market.
Key Highlights
- 1Completed a secondary stock offering of 14,375,000 shares of common stock on May 25, 2023.
- 2Raised approximately $380.5 million in net proceeds after deducting underwriting discounts and estimated expenses.
- 3The offering price was $28.00 per share, with the company selling shares at $26.53 to underwriters before accounting for discounts.
- 4The underwriters fully exercised their option to purchase an additional 1,875,000 shares.
- 5A customary 60-day lock-up period is in effect for the company and its directors and executive officers, restricting the sale of shares without consent.
- 6The offering was made under an effective shelf registration statement on Form S-3.
- 7The proceeds are intended to further the company's growth and operational objectives.
Frequently Asked Questions
The primary purpose of this offering was to raise additional capital for Guardant Health, Inc. While not explicitly stated in this 8-K filing, such offerings are typically undertaken to fund ongoing operations, invest in research and development, expand commercialization efforts, and for general corporate purposes, strengthening the company's financial position.
Guardant Health received approximately $380.5 million in net proceeds from the offering. This amount is after deducting the underwriters' discounts and commissions, as well as estimated offering expenses.
Yes, Guardant Health and its directors and executive officers have agreed not to sell or transfer any shares of common stock for 60 days after the date of the prospectus supplement, unless they obtain prior written consent from the lead underwriters. This is a standard 'lock-up' provision designed to stabilize the stock price post-offering.
A shelf registration statement (Form S-3 in this case) allows a company to register securities for sale in advance. This means that when market conditions are favorable, the company can "take down" from the shelf and quickly offer and sell a portion of those registered securities, as Guardant Health did with this offering.